Key Drivers
- Margin Pressure
- Negative Free Cash Flow
- Liquidity Decline
AIAI Summary
STVN is evolving into a higher-margin drug-delivery platform, but the investment hinges on Fishers and Latina converting high-value-product growth into sustained free-cash-flow generation; investors should favor the shares only if capacity utilization and working-capital discipline improve without further execution delays.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Pressure
- •Negative Free Cash Flow
- •Liquidity Decline
STVN remains profitable with stable gross margins and modestly lower debt, but weakening quarterly margins, negative free cash flow, declining liquidity, rising inventory, and richer valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Resistance rejection
- •Key support zone
- •Breakout needed
STVN is range-bound over the last month, with support at $20.20–$20.50 and resistance at $22.50–$22.70; hold support or wait for a breakout above resistance after the recent rejection.
Sharp drop from $22.67 on 2026-09-17 to $21.70 on 2026-09-18
Sentiment & News
Key News Insights:
- •Share Price Weakness
- •Premium Mix Growth
- •Capacity Expansion
Stevanato's share pullback may present value upside, supported by its shift toward higher-margin drug-delivery solutions, expanding capacity, and upcoming investor conferences.
Near-term sentiment is weak, but operational transformation and valuation support could improve the stock's longer-term outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings